Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) and Trevena (NASDAQ:TRVN – Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Decoy Therapeutics and Trevena, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Decoy Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Trevena | 0 | 0 | 0 | 0 | 0.00 |
Decoy Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 443.48%. Given Decoy Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Decoy Therapeutics is more favorable than Trevena.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Decoy Therapeutics | N/A | N/A | -$12.52 million | ($106.90) | -0.05 |
| Trevena | $443,000.00 | 0.00 | -$40.29 million | ($47.04) | 0.00 |
Decoy Therapeutics has higher earnings, but lower revenue than Trevena. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Decoy Therapeutics and Trevena’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Decoy Therapeutics | N/A | -395.42% | -193.30% |
| Trevena | N/A | N/A | -119.55% |
Volatility and Risk
Decoy Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Trevena has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.
Insider & Institutional Ownership
11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 1.7% of Decoy Therapeutics shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Trevena beats Decoy Therapeutics on 7 of the 12 factors compared between the two stocks.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
About Trevena
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
